Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2000

View Archived Issues

Oncolytics Biotech's pilot canine study of Reolysin shows measurable tumor response

ImmuCell reports positive preliminary results from DiffGAM phase I/II clinical trial

AOP Orphan to distribute Uniprost in select European countries

ImClone Systems awarded SBIR grant for antiangiogenesis research

Anti-CD11a enters phase I/II study in kidney transplant patients

Medarex and Raven Biotechnologies form antibody development collaboration

EntreMed commences phase I clinical trial of 2-methoxyestradiol

FDA advisory committee recommends approval of Activa Parkinson's Control Therapy

Medivir to acquire Mimetrix

Xenova highlights 1999 clinical progress

New xanthine oxidase inhibitors designed by Yamasa Shoyu

Japan Energy describes preparation and use of cPLA2 inhibitors

Japanese lab presents new quinazoline chymase inhibitors

Chugai's new motilin antagonists useful for IBS

Ring-modified cyclic peptide analogues of echinocandin in development at Lilly

Novel inhibitors of cyclin-dependent kinases discovered by Korean researchers

Binding, functional and pharmacological characterization of R-113281

Licensing opportunity from NIH: adenovirus-mediated gene therapy

Eisai describes pharmacological profile of candidate for hypertension and heart failure

Mallinckrodt launches new MRI contrast agent in U.S.

AHP announces first launch of Prevnar

More ACS highlights: discovery of potent class III antiarrhythmic agent RWJ-28810

SB-238039: a new antitumor agent that appears to act as a Jak2 inhibitor

Avandia receives FDA approval for treatment of type II diabetes in combination with sulfonylureas

Anxiolytic development candidate selected by Dainippon based on promising pharmacological profile

Simplified halichondrin B analogues retain potent anticancer activity

Structure, preclinical and clinical data for BMS-193884 presented at ACS meeting

T-900607, a novel tubulin-binding agent, on track for clinical development

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...